Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Recommendation of "Buy" from Analysts

Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) has received a consensus rating of "Buy" from the nine research firms that are presently covering the company, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $13.38.

A number of analysts have recently weighed in on CMPX shares. Piper Sandler started coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 target price for the company. D. Boral Capital restated a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Monday. HC Wainwright reiterated a "buy" rating and issued a $24.00 price target on shares of Compass Therapeutics in a report on Monday, April 21st. Wedbush reiterated an "outperform" rating and issued a $8.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 1st. Finally, Guggenheim restated a "buy" rating on shares of Compass Therapeutics in a report on Tuesday, April 22nd.

Insider Transactions at Compass Therapeutics

In other Compass Therapeutics news, insider Jonathan Anderman purchased 20,000 shares of the stock in a transaction that occurred on Monday, April 7th. The shares were acquired at an average cost of $1.54 per share, with a total value of $30,800.00. Following the completion of the transaction, the insider now owns 21,000 shares in the company, valued at $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Carl L. Gordon sold 3,571,428 shares of the firm's stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 28.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds have recently bought and sold shares of the company. MPM Bioimpact LLC increased its holdings in Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after buying an additional 2,926,002 shares during the period. Enavate Sciences GP LLC acquired a new stake in shares of Compass Therapeutics in the 4th quarter valued at approximately $11,293,000. Tang Capital Management LLC boosted its stake in shares of Compass Therapeutics by 225.4% in the 4th quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after purchasing an additional 4,087,005 shares in the last quarter. Rock Springs Capital Management LP boosted its stake in shares of Compass Therapeutics by 2.7% in the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock valued at $8,380,000 after purchasing an additional 150,336 shares in the last quarter. Finally, Blue Owl Capital Holdings LP boosted its stake in shares of Compass Therapeutics by 2.6% in the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock valued at $4,284,000 after purchasing an additional 75,000 shares in the last quarter. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock traded down $0.04 during trading on Friday, reaching $1.90. The company's stock had a trading volume of 553,490 shares, compared to its average volume of 876,323. The business's fifty day moving average price is $2.20 and its 200-day moving average price is $2.10. The firm has a market cap of $262.74 million, a price-to-earnings ratio of -5.13 and a beta of 1.40. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). Sell-side analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.